Vir Biotechnology VIR

$ 6.95 3.12%

Quarterly report 2024-Q3
added 11-04-2024

Vir Biotechnology Balance Sheet 2011-2024 | VIR

Annual Balance Sheet Vir Biotechnology

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-117 M	-721 M	-210 M	-366 M	-109 M	-47.6 M	-188 M	-	-	-	-	-	-
Long Term Debt	112 M	124 M	134 M	66.6 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	12.9 M	4.14 M	3.93 M	3.62 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	28.9 M	331 M	308 M	-	-	-	-	-	-
Total Current Liabilities	175 M	511 M	341 M	99.1 M	59.2 M	-	-	-	-	-	-	-	-
Total Liabilities	329 M	724 M	522 M	202 M	88.1 M	371 M	320 M	-	-	-	-	-	-
Deferred Revenue	64.9 M	15.5 M	98.2 M	6.45 M	6.18 M	8.76 M	-	-	-	-	-	-	-
Retained Earnings	-238 M	377 M	-139 M	-	-369 M	-194 M	-78 M	-	-	-	-	-	-
Total Assets	1.92 B	2.8 B	1.95 B	919 M	512 M	192 M	252 M	-	-	-	-	-	-
Cash and Cash Equivalents	242 M	849 M	348 M	437 M	109 M	47.6 M	189 M	-	-	-	-	-	-
Book Value	1.59 B	2.08 B	1.43 B	717 M	424 M	-179 M	-68.9 M	-	-	-	-	-	-
Total Shareholders Equity	1.59 B	2.08 B	1.43 B	717 M	424 M	-179 M	-68.9 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Vir Biotechnology

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	93.4 M	95 M	109 M	112 M	114 M	118 M	121 M	124 M	127 M	130 M	133 M	134 M	68.6 M	68.9 M	66.6 M	700 K	700 K	800 K	800 K	900 K	900 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	258 M	236 M	247 M	329 M	370 M	434 M	695 M	724 M	546 M	667 M	886 M	522 M	334 M	320 M	485 M	202 M	202 M	202 M	202 M	88.1 M	88.1 M	88.1 M	88.1 M	61.6 M	61.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	15.2 M	16.7 M	14.7 M	64.9 M	15.3 M	15.7 M	17.2 M	15.5 M	22.9 M	113 M	114 M	98.2 M	96.2 M	44.7 M	263 M	6.45 M	6.45 M	6.45 M	6.45 M	6.18 M	6.18 M	6.18 M	6.18 M	8.76 M	8.76 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-655 M	-441 M	-303 M	-238 M	-122 M	41.6 M	236 M	377 M	479 M	304 M	380 M	-139 M	-664 M	774 M	-836 M	-667 M	-667 M	667 M	-667 M	-369 M	-369 M	-369 M	-369 M	-194 M	-194 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	1.5 B	1.67 B	1.79 B	1.92 B	2.04 B	2.24 B	2.67 B	2.8 B	2.7 B	2.62 B	2.89 B	1.95 B	1.21 B	1.06 B	1.14 B	919 M	919 M	919 M	919 M	512 M	512 M	512 M	512 M	192 M	192 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	168 M	297 M	161 M	242 M	452 M	667 M	825 M	849 M	964 M	1.51 B	812 M	348 M	715 M	742 M	521 M	451 M	437 M	437 M	437 M	109 M	109 M	109 M	109 M	47.6 M	47.6 M	-	-	188 M	-	-	-	14.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	1.24 B	1.43 B	1.55 B	1.59 B	1.68 B	1.81 B	1.97 B	2.08 B	2.15 B	1.95 B	2 B	1.43 B	876 M	737 M	651 M	717 M	717 M	717 M	717 M	424 M	424 M	424 M	424 M	130 M	130 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	1.24 B	1.43 B	1.55 B	1.59 B	1.68 B	1.81 B	1.97 B	2.08 B	2.15 B	1.95 B	2 B	1.43 B	876 M	737 M	651 M	717 M	717 M	717 M	717 M	424 M	424 M	424 M	424 M	-179 M	-179 M	-122 M	-	-68.9 M	-	-	-	-7.97 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency